Last reviewed · How we verify
NCT01882322: Maple
A Study to Evaluate the Effect of Advagraf Conversion From Prograf in Liver Transplant Subjects
Phase 4 trial testing Prograf in de Novo Liver Transplant Subjects in 36 participants. Completed in 3 January 2017.
3 January 2017
Quick facts
| Lead sponsor | Astellas Pharma Korea, Inc. |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 30 January 2013 |
| Primary completion | 3 January 2017 |
| Estimated completion | 3 January 2017 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
Conditions studied
- de Novo Liver Transplant Subjects — all drugs for de Novo Liver Transplant Subjects →
Sponsor
Astellas Pharma Korea, Inc. — full company profile →
Who can join
Adults 20 to 65, any sex, with de Novo Liver Transplant Subjects. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to compare the efficacy and safety between a group that has been on Prograf twice daily therapy but converted to Advagraf once daily therapy and a group that maintained Prograf twice daily therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01882322
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Prograf
Trials testing the same drug.
- NCT05655273 — Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients · Phase 4 · enrolling by invitation
- NCT03828058 — Envarsus XL Immunosuppression Following Liver Transplantation · Phase 2 · completed
- NCT02866682 — Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in · Phase 4 · completed
- NCT03216447 — A Study of Patient Adherence and Convenience to Immunosuppressive Agents in Newly Liver Transplant · Phase 4 · unknown
- NCT02251691 — Influence of Once-daily Versus Twice-daily Immunosuppressant on Renal Transplant · Phase 4 · unknown
Other Astellas Pharma Korea, Inc. trials
Trials by the same sponsor.
- NCT06902545 — A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction · recruiting
- NCT06452212 — Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients · completed
- NCT06011954 — A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection · recruiting
- NCT04691648 — A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Li · completed
- NCT03737708 — A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA) · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01882322 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Astellas Pharma Korea, Inc.
- Last refreshed: 31 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01882322.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing